Editas Medicine is a discovery-phase pharmaceutical company based in Cambridge, Massachusetts which aims to develop therapies based on CRISPR–Cas9 gene editing technology. The company went public on 2 Feb 2016. This initial public offering was noted as being the first such from a company which aims to use "DNA itself to internally treat afflictions". The company has conceded that “It will be many years, if ever, before we have a product candidate ready for commercialization.” Further, the company's valuation depends on a single patent, which holder was in dispute as of early 2016, presenting a major risk to the company's continued viability.
The company entered into a strategic collaboration with Juno Therapeutics in 2015 to combine its CRISPR-Cas9 technology with Juno's experience in creating chimeric antigen receptor and high-affinity T cell receptor therapeutics to the end of developing cancer therapeutics.
The company announced in 2015 that it was planning a clinical trial in 2017 using CRISPR gene editing techniques to treat Leber's congenital amaurosis, a rare genetic illness that causes blindness.
NPS is a customer loyalty metric that measures customers’ willingness to not only return for another purchase or service but also make a recommendation to their family, friends or colleagues.
It is a powerful and effective technique, which can greatly increase a company's revenue if used properly.
The main advantages of NPS are close correlation with a company's growth and easy collection, interpretation and communication of the data.
Yes, it is.
Net Promoter Score is a number from -100 from 100.
Scores higher than 0 are typically considered to be good and scores above 50 are considered to be excellent.
The industry average for Health Care / Biotechnology: Biological Products (No Diagnostic Substances) is 0.
The final Net Promoter Score of a company strongly depends on a context in which the satisfaction is measured.
Consider an example: If Editas Medicine, Inc. sends out NPS surveys immediately after purchase, they are tracking their customers' initial excitement and the checkout experience.
On the other hand, if they survey their customers a few weeks after the purchase they are also tracking how satisfied their customers are with their products and services over time.
Therefore, comparing the NPS score of Editas Medicine, Inc. with your own without any further context is not that useful.
What is extremely useful though, is using the NPS methodology to track the satisfaction of your customers over time. That's where Customer.guru comes in.
|Visa||Financial Services / Credit cards||8|
|J.P. Morgan||Financial Services / Banking||8|
|Allianz||Financial Services / Banking||8|
|O2||Telecommunications / Wireless Carrier||7|
|Virgin Mobile UK||Telecommunications / Wireless Carrier||7|
|Verizon||Telecommunications / Cable/TV service||7|
|Lyft||Travel and Hospitality / Car Rental||9|
|Yahoo!||Consumer Brands / Internet||9|
|TD Bank||Financial Services / Banking||10|
|Sprint||Telecommunications / Wireless Carrier||5|
We have estimated the Net Promoter Score of Editas Medicine, Inc. based on the publicly available information
including the sentiment of the company-related tweets, 3rd party reviews, and Alexa ratings.